Loading
A phase 3 trial in Iran found that a locally made copy of pertuzumab, given before surgery, cleared tumours from the breast as often as the original.
214 chemotherapy-naive women with HER2-positive breast cancer were randomised 1:1 to six cycles of P013 (CinnaGen) or Perjeta (Roche) with trastuzumab, carboplatin and docetaxel every three weeks, stratified by cancer type and hormone receptor status. The primary endpoint was breast pathological complete response. A correction was published in BMC Cancer in 2022 (DOI 10.1186/s12885-022-10455-0).
A pertuzumab made in Iran has now been tested against the original, beside the locally made trastuzumab it is given with. A 2025 analysis of Iran's breast cancer services nevertheless listed pertuzumab among four medicines not covered by health insurance.
Shares Biosimilar, Trastuzumab, HER2, HER2-positive breast cancer.
Shares Biosimilar, Trastuzumab, HER2, HER2-positive breast cancer.
Shares CinnaGen, Biosimilar, Pertuzumab, Trastuzumab.
Shares CinnaGen, Biosimilar, Trastuzumab, HER2-positive breast cancer.
Shares Trastuzumab, HER2, HER2-positive breast cancer.
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer.
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer.
Shares Pertuzumab, Trastuzumab, HER2-positive breast cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/